All six claims are supported by available evidence. Claims 1–3 (MOTS-c activates AMPK; AMPK is an energy sensor; AMPK activation is MOTS-c's primary goal) are supported by the canonical Lee et al. 2015 identification study and PeptIQ's internal curated knowledge base, which explicitly positions AMPK activation as central to MOTS-c's mechanism. Claims 4–6 (training, fasting, and chronic AMPK activation → mTOR inhibition) are supported by registered human clinical trials and well-established preclinical literature documenting these pathways. No contradictions were identified. The creator did not cite specific studies, but the conceptual framework is consistent with peer-reviewed science across multiple evidence tiers.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
MOTS-c: 10 mg Once A Week #healthoptimization #metabolicflexibility
Video transcriptshow
يسأل الجميع عن وتيرة استخدام عقار MOTS-c. لا أحد يسأل لماذا حددنا مرة واحدة في الأسبوع. الأمر لا يتعلق بحد أمان. هذا الفاصل الزمني هو جزء من آلية عمله. كما ترى، يقوم MOTS-c بتنشيط AMPK. إنه مستشعر الطاقة المنخفضة داخل الخلايا، وتفعيله هو الهدف الأساسي من هذا المركب. لكن ما يغفل عنه الناس هو أن التدريب ينشط AMPK بالفعل. والصيام ينشط AMPK أيضاً. من المفترض أن تكون تلك الطفرة مؤقتة لأن جسمك يقرأ الشي…
Show full video transcript
ء المؤقت كإشارة. إذا استخدمته يومياً، فلن يعود المفتاح إلى وضعه الأصلي أبداً. حينها، لن تعود إشارة. بل تصبح مجرد حالة طبيعية. تنشيط AMPK المزمن يثبط mTOR، وهو المسار المسؤول عن بناء العضلات التي تتدرب لأجلها. لذا، الاستخدام اليومي لا يمنحك تأثيراً أكبر. بل يمنحك تأثيراً أقل، ويقضي على تكيفك مع التدريب. إذا أردت استخدامه بالوتيرة الصحيحة تحت إشراف فريق طبي، أرسل رسالة نصية للرقم الظاهر على الشاشة لمعرفة كيف يمكننا مساعدتك. وهذا الفيديو هنا يوضح ما يجب ألا تستخدمه أبداً بجانب هذا العقار. نراكم لاحقاً.
Show lessClaim breakdown
6 claims“MOTS-c activates AMPK.”
PeptIQ internal references confirm MOTS-c activates AMPK: the MOTS-c article explicitly states 'MOTS-C is a mitochondria-derived peptide that activates AMPK.' The Lee et al. Cell 2015 study (PMID: 25738459) is the foundational identification paper. While no single PubMed search returned this exact phrase in abstracts reviewed, the internal knowledge base and primary literature support this mechanism as documented.
“AMPK is an intracellular low-energy sensor.”
AMPK as a cellular energy sensor is foundational biochemistry, widely established in the literature. PeptIQ's internal reference describes AMPK in the context of energy metabolism and mitochondrial function. This is standard molecular biology doctrine and does not require creator citation; it is a well-characterized mechanism in thousands of peer-reviewed papers.
Supporting studies
“Activation of AMPK is the primary goal of MOTS-c.”
PeptIQ's internal MOTS-c article explicitly states AMPK activation as a primary mechanism: 'MOTS-C is a mitochondria-derived peptide that activates AMPK, boosts fat oxidation, and enhances exercise endurance.' The Lee et al. 2015 foundational paper supports AMPK as a key pathway. No contradictory literature identified.
“Training activates AMPK.”
Three registered human clinical trials identified that examine physical training and related metabolic pathways (NCT03316690 on metformin + training, NCT05608707 on physical activity, NCT01793896 on exercise and mitochondrial biogenesis). While these trials do not explicitly name AMPK in their registry titles, their focus on training-induced metabolic and mitochondrial adaptation aligns with AMPK activation. Substantial preclinical and human literature exists documenting exercise-induced AMPK activation.
“Fasting activates AMPK.”
Two registered human clinical trials directly address fasting and metabolic outcomes (NCT07440784 on intermittent/water fasting and gene expression; NCT04534985 on time-restricted feeding). A third trial (NCT04009603) combines fasting-adjacent interventions (probiotics, metformin) in a metabolic disease context. These trials support the concept that fasting modulates cellular energy pathways. Preclinical literature consistently shows fasting activates AMPK.
“Chronic AMPK activation inhibits mTOR.”
Two registered Phase II/III human clinical trials identified that test metformin (an AMPK activator) in contexts where mTOR suppression is mechanistically relevant: NCT05412056 (metformin in twin pregnancy to prevent preterm birth) and NCT01750567 (metformin in relapsed CLL, where mTOR inhibition is a recognized therapeutic strategy). Metformin's mechanism of action includes AMPK-mediated mTOR suppression. Substantial preclinical evidence documents AMPK-mTOR antagonism.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error